8-K: ZyVersa Secures $1M in Convertible Notes, Warrants

ZyVersa Therapeutics, Inc. has raised $1 million through a private placement of convertible promissory notes and common stock purchase warrants to accredited investors for working capital.

Summary

• ZyVersa Therapeutics, Inc. entered into a Securities Purchase Agreement on February 27, 2026, to issue and sell convertible promissory notes and Series A-4 Common Stock Purchase Warrants to accredited investors.
• The aggregate principal amount of the convertible promissory notes is $1 million, bearing interest at 10% per annum (compounded annually) and maturing on February 27, 2027.
• Notes are convertible into common stock at a price equal to 80% of a Qualified Offering price or 80% of the lowest daily volume-weighted average price (VWAP) during the 10 trading days prior to conversion, with a floor price of $0.02 per share.
• The Series A-4 Common Stock Purchase Warrants are exercisable starting August 27, 2026, and expire on February 27, 2031.
• The warrant exercise price is 110% of a Qualified Offering price or 110% of the 5-trading-day VWAP (181st-185th day after issuance) if no Qualified Offering occurs by the initial exercise date.
• A 'Qualified Offering' is defined as an equity financing where the company receives at least $15 million in net proceeds from the sale of common stock or convertible securities.
• The company intends to use the net proceeds from this offering for working capital purposes.
• The obligations under the notes are guaranteed by ZyVersa Therapeutics Operating, Inc., a wholly-owned subsidiary.
• The company has agreed to file a resale registration statement for the shares issuable upon conversion of the notes within six months of the issuance date and for the warrant shares within 30 days of the initial exercise date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a necessary capital infusion for working capital, providing liquidity to sustain operations. While it addresses immediate funding needs, the potential for future dilution from the convertible notes and warrants, especially with a low conversion floor price, presents a mixed outlook for existing shareholders.

Positives

• Secured $1 million in financing, providing essential working capital for the company's operations.
• The convertible notes bear a 10% interest rate, offering a return to investors.
• The notes are guaranteed by a wholly-owned subsidiary, ZyVersa Therapeutics Operating, Inc., adding a layer of security for noteholders.
• The company has committed to filing resale registration statements for the underlying shares, which facilitates liquidity for investors.

Negatives

• The conversion price for the notes and exercise price for the warrants are variable and can be tied to future market prices, potentially leading to significant dilution for existing shareholders if the stock price declines.
• The $0.02 floor price for note conversion is relatively low, indicating a high potential for dilution if the stock trades near or below this level.
• Restrictions on the company include not redeeming or paying dividends on its securities while the notes or warrants are outstanding, and prohibitions on variable rate transactions while the notes are outstanding, limiting financial flexibility.
• The financing is for 'working capital purposes,' which often suggests funding ongoing operations rather than specific growth initiatives, potentially indicating a need for liquidity.

Risks

• Failure to file or maintain effectiveness of the required resale registration statements could impact the liquidity of the underlying shares for investors.
• Significant dilution for existing shareholders could occur upon conversion of the notes and exercise of the warrants, especially if the stock price is low.
• The variable conversion and exercise prices expose the company to market price fluctuations, potentially leading to more shares being issued than anticipated.
• The company's ability to raise a 'Qualified Offering' of at least $15 million will influence the final conversion and exercise prices, and failure to do so could result in less favorable terms for the company.

Future Outlook

The company plans to use the net proceeds for working capital. It is obligated to file resale registration statements for the shares underlying the convertible notes within six months of issuance and for the warrant shares within 30 days of the warrants' initial exercise date. The terms of the notes and warrants are designed to adjust based on future equity financings or market performance.

Industry Context

StockSavvy.ai notes that this type of private placement, involving convertible notes and warrants, is a common financing strategy for early-stage biotechnology or pharmaceutical companies like ZyVersa Therapeutics, especially those listed on the OTCQB Venture Market. It allows them to secure necessary capital for ongoing operations and research and development without immediately undertaking a larger, more complex public offering. The structure provides investors with potential upside through equity conversion while offering debt-like protection.

Comparison to Industry Standards

• StockSavvy.ai observes that the 10% annual interest rate on the convertible notes is within the typical range for private placements to accredited investors in the biotech sector, reflecting the risk profile of such ventures.
• The $0.02 floor price for note conversion is relatively low, which could lead to substantial dilution for existing shareholders if the company's stock price remains depressed or declines further, a common characteristic in highly speculative early-stage companies.
• The inclusion of warrants with an exercise price at 110% of a future offering or VWAP is standard practice in such private placements, providing additional upside for investors while aligning with market-based valuation mechanisms.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential future dilution from the conversion of notes and exercise of warrants, especially given the variable pricing mechanisms and low floor price.
• Noteholders (Investors): Benefit from a 10% interest rate, a subsidiary guarantee, and the potential for equity upside through conversion rights, with provisions for anti-dilution and registration of shares.
• Employees: The securing of working capital helps ensure continued operations, which is positive for job security and ongoing projects.
• Creditors: The notes are unsecured obligations of the company but are guaranteed by a subsidiary, which provides some level of assurance.

Next Steps

• File a resale registration statement covering the shares of Common Stock issuable upon conversion of the Notes within six months of the issuance date (by August 27, 2026).
• File a resale registration statement covering the shares of Common Stock issuable upon Warrant exercise within 30 days of the Initial Exercise Date (by September 26, 2026).
• Continue to use net proceeds for working capital purposes.

Key Dates

Recommendation

The capital raise provides essential working capital, which is positive for the company's operations and stability. However, the convertible notes and warrants introduce significant potential for future dilution, especially given the low conversion floor price, which could pressure the stock price. A 'Hold' recommendation reflects the balance between immediate liquidity and long-term dilution concerns, suggesting investors monitor the company's operational progress and future financing activities.

Keywords

ZyVersa Therapeutics, ZVSA, convertible notes, warrants, private placement, capital raise, working capital, SEC filing, equity financing, biotech, pharmaceuticals